WILMINGTON, Mass., March 7, 2012 (GLOBE NEWSWIRE) -- DUSA Pharmaceuticals, Inc.® (Nasdaq:DUSA), a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT), announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the Roth 24th Annual OC Growth Stock Conference. The conference is being held at the Ritz-Carlton, Laguna Niguel, California, March 12-14, 2012. Mr. Doman is scheduled to present at 1:00 p.m. Pacific Time (4:00 p.m. Eastern Time) on March 13, 2012. Interested parties can click here to access the live audio webcast of the presentation or visit our website at www.dusapharma.com. An archived version of the presentation will be available on the DUSA website approximately six hours following the presentation.
About DUSA Pharmaceuticals
DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan® PDT technology platform. Levulan® Kerastick® (aminolevulinic acid HCl) for Topical Solution, 20% plus blue light illumination using DUSA's BLU-U® Blue Light Photodynamic Therapy Illuminator is currently approved for the treatment of minimally to moderately thick actinic keratoses (AKs) of the face or scalp. DUSA is based in Wilmington, Mass. Please visit our website at www.dusapharma.com.